TY - JOUR
T1 - Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity
T2 - Impact of hepatitis C coinfection
AU - French, Audrey L.
AU - Benning, Lorie
AU - Anastos, Kathryn
AU - Augenbraun, Michael
AU - Nowicki, Marek
AU - Sathasivam, Kunthavi
AU - Terrault, Norah A.
N1 - Funding Information:
Financial support. The National Institute of Allergy and Infectious Diseases, with supplemental funding from the National Cancer Institute, the National Institute of Child Health & Human Development, the National Institute on Drug Abuse, and the National Institute of Craniofacial and Dental Research (grants U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-HD-32632, U01-AI-34993, U01-AI-42590, M01-RR00079, and M01-RR00083). Conflict of interest. All authors: No conflict.
PY - 2004/8/1
Y1 - 2004/8/1
N2 - To characterize longitudinal hepatic toxicity of antiretroviral therapy in HIV-infected women with and without hepatitis C virus (HCV) infection, we measured alanine and aspartate aminotransferase values among women initiating highly active antiretroviral therapy (HAART). For 312 HIV/HCV coinfected women who received HAART for a mean of 1.8 years, the prevalence of elevated aminotransferase levels >3 times and >5 times the upper limit of normal (ULN) was low (<12% and <4%, respectively), and the prevalence of elevated aminotransferase levels declined over time. When we analyzed trends in aminotransferase levels according to type of HAART received among HCV-infected and uninfected women, we found that mean aminotransferase levels declined among 539 women receiving therapy with protease inhibitors (decreases of 5.34%-4.23% of the ULN per year; P values for trend of .007-.06), but mean values among 128 women receiving therapy with non-nucleoside reverse-transcriptase inhibitors remained stable (from decreases of 1.65% to increases of 7.57% of the ULN per year; P values of .19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection.
AB - To characterize longitudinal hepatic toxicity of antiretroviral therapy in HIV-infected women with and without hepatitis C virus (HCV) infection, we measured alanine and aspartate aminotransferase values among women initiating highly active antiretroviral therapy (HAART). For 312 HIV/HCV coinfected women who received HAART for a mean of 1.8 years, the prevalence of elevated aminotransferase levels >3 times and >5 times the upper limit of normal (ULN) was low (<12% and <4%, respectively), and the prevalence of elevated aminotransferase levels declined over time. When we analyzed trends in aminotransferase levels according to type of HAART received among HCV-infected and uninfected women, we found that mean aminotransferase levels declined among 539 women receiving therapy with protease inhibitors (decreases of 5.34%-4.23% of the ULN per year; P values for trend of .007-.06), but mean values among 128 women receiving therapy with non-nucleoside reverse-transcriptase inhibitors remained stable (from decreases of 1.65% to increases of 7.57% of the ULN per year; P values of .19-.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection.
UR - http://www.scopus.com/inward/record.url?scp=3943052712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3943052712&partnerID=8YFLogxK
U2 - 10.1086/422142
DO - 10.1086/422142
M3 - Article
C2 - 15307009
AN - SCOPUS:3943052712
SN - 1058-4838
VL - 39
SP - 402
EP - 410
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -